Intratumoral Fusobacterium as a prognostic and predictive biomarker in resectable colorectal cancer

The archetypal results from the multicenter FUSOMAP project, published successful ESMO Open and led by VHIO's Molecular Oncology Group, amusement that the beingness of intratumoral Fusobacterium successful surgical tumor samples identifies a clinically much assertive subtype of colorectal crab (CRC), characterized by a weaker immune response, constricted payment from adjuvant chemotherapy pursuing country and an accrued hazard of illness recurrence. These findings enactment the imaginable usage of Fusobacterium arsenic a prognostic and predictive biomarker successful patients with resectable CRC.